Cipla Ltd. — Investor Presentation 2026

May 13, 2026

Cipla

$13^{\text{th}}$ May, 2026

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, $5^{\text{th}}$ floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Symbol: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Investor Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation dated $13^{\text{th}}$ May, 2026.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Cipla Limited

RAJENDR
A CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.05.13
12:56:47 +05'30'

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Neelam Padwad

Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

---

Cipla

Investor Presentation

Q4FY26

13-05-2026

---

Cipla

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

---

Cipla

Highest-ever Yearly Revenue; Despite Multiple Headwinds

	Revenue	EBITDA	PAT
Q4FY26	INR 6,541 Cr	INR 997 Cr
(15.2% Margin)	INR 555 Cr
(8.5% Margin)
FY26	INR 28,163 Cr	INR 5,925 Cr
(21.0% Margin)	INR 3,879 Cr
(13.8% Margin)

Business Performance Snapshot

	One India	North America	One Africa	Emerging Markets & Europe
Q4FY26	INR 3,007Cr ↑15% (YoY)	$ 155 Mn	$ 135 Mn ↑14% (YoY)	$ 90 Mn
FY26	INR 12,680 Cr ↑9% (YoY)	$ 780 Mn	$ 483 Mn ↑7% (YoY)	$ 405 Mn
	Delivered double-digit growth across 3 segments in Q4 FY26	Received approval for the first AB-rated gVentolin with CGT	SA private growing at a market¹ growth multiple of 1.4x	Crossed $ 400 Mn benchmark

1. Market data as per IQVIA MAT Feb'26

---

Financial Performance : Q4FY26

Cipla

Revenues INR 6,541 Cr

EBITDA INR 997 Cr

Q4FY26 (Consolidated)
	G4FY26 (INR Cr)	G4FY25 (INR Cr)
Total Revenue from Operations	6,541	6,730
EBITDA	997	1,538
EBITDA %	15.2%	22.8%
PAT	555	1,222
PAT %	8.5%	18.2%

R&D² INR 509 Cr | 7.8% of revenue

1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation

---

Cipla

Financial Performance : FY26

Revenues

INR 28,163 Cr

EBITDA

INR 5,925 Cr

FY26 (Consolidated)
	FY 26
(INR Cr)	FY25
(INR Cr)
Total Revenue from Operations	28,163	27,548
EBITDA	5,925	7,128
EBITDA %	21.0%	25.9%
PAT	3,879	5,273
PAT %	13.8%	19.1%

R&D² INR 1,974 Cr | 7.0% of revenue

1. India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation

---

Cipla
INR Cr

Strategic Focus Across Key Financial Metrics¹

1. FY23 and FY24 are Ex-QCIL

---

Cipla
INR Cr

Strong Net-Cash : Assembling Resources to Fuel Growth Investments; $ 1 Bn+ Net Cash Position in our Balance Sheet

Total Debt

Total Cash

1. Cash & cash equivalents includes current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances

---

One India¹: Building a Sustainable Legacy for Enduring Growth

Cipla

One India Business

FY26 Revenue INR 12,680 Cr

Q4FY26 Revenue INR 3,007 Cr

Achieved robust double-digit growth across three segments

Branded Prescription

• Cipla maintained #2 rank in overall chronic with improved chronic mix² to 60.2%
• Launched key products like Voltido Trio Ciphaler, Huena, Zemdri, and Empacip during the year
• Double-digit growth² in chronic therapies like Respiratory, Urology, Anti-diabetes and Cardiac

Trade Generics

• Posted strong growth supported by robust performance across key categories
• 3 Brands with TTM revenue of > INR 100 Cr and 4 Brands with TTM revenue of INR 50 Cr to INR 100 Cr
• 17 new launches in FY26

Consumer Health

• Delivered a robust double-digit growth with anchor & transitioned brands continuing to grow bigger
• Sustained EBITDA margin trajectory

• Nicotex, Omnigel and Cipladine maintained their leadership positions in the market

• India includes Branded Prescription, Trade Generics and Consumer Health | 2. Market data as per IQVIA MAT Mar'26

---

Cipla

India Branded Prescription¹ : Advancing with Strategic Precision

Double-Digit Growth in Key Therapies (%)

Rank

Our in-house brand franchise, Dytor, has scaled to over INR 650 Cr

Foracort surpassed the INR 1,000 Cr milestone in IPM

Respiratory supremacy, with Cipla's brands occupying all top 5 spots in the category

Key Market Highlights

| Foracort
Biggest Respiratory Brand in the IPM | 23 Brands
IPM Brands in Top 300 ranks | 33 Brands
IPM Brands with revenue >INR 100 Cr | 7 Therapies
With IPM Top 5 ranks |
| --- | --- | --- | --- |

1. Market data as per IQVIA MAT Mar'26

---

Cipla

Portfolio-Enhancing Introductions : Powering a Year of New Launches

Respiratory

Foracort G Synchrobreathe and Ciphaler

Enhancing adherence with intuitive device-led therapy for superior asthma & COPD control

voltido Trio 100 ciphaler®

Triple-action power for consistent bronchodilation & inflammation control in 1 device

AMR

A breakthrough for cUTI - effective beyond conventional choices

Cipenmet + Esblocip

Targeting resistant pathogens with a robust BL/BLI combination for critical infection

Urology

AMR in UTI - Non antibiotic prophylaxis management option for recurrent UTI

XTIKTR
Regenerators Calls, Restores Flow

Regenerative therapy addressing root causes to restore urinary function

Anti-diabetes

Comprehensive SGLT2-led portfolio enabling holistic glycemic management

Dermatology

Innovative therapy transforming hypertrophic scar management with improved patient outcomes

---

Cipla's Strategic Alliances : Unlocking Value Through Partnerships & Acquisitions

Cipla

Key Strategic Transactions during the Year

yurpeak

Secured rights from Eli Lilly to distribute and promote Yurpeak® in India

Pfizer

Exclusive marketing and distribution rights for key brands (Corex, Dolonex, Neksium, Dalacin C)

CiploStem

Launched Ciplostem, a DCGI-approved allogeneic MSC therapy for Knee Osteoarthritis

afrezza

Preventive products for the treatment of chronic inflammatory conditions

Participated in the treatment of chronic inflammatory conditions

Partnered with MannKind to launch India's only rapid acting inhaled insulin

Doloneuron

Doloneuron NT

Zolsoma

Strengthened Neuro/CNS via acquisition of 3 brands to address neuropathic pain & sleep disorders

INZPERA

Healthy Habits. Nappler Lives

100% stake acquisition, adding a differentiated pediatrics & wellness portfolio

---

India Trade Generics : Establishing Deeper Connect with Strong Growth Levers

Cipla

1

India's Largest Trade Generic Business

5,500+ Stockiest Network

150,000+ Chemist coverage

15,000+ Pin codes serviced

400+ Retail field team (RTF)

Big Brands Bigger

3 Brands with Revenue > INR 100 Cr

Key New Launches

---

Cipla

FY26 : Global Consumer Wellness Franchise

One India

OMNIGEL®
Pain Relief

nicotex
Smoking Cessation

prolyte® ORS
Hydration

cofsils
Cold & Cough

CIPLADINE®
Skin Infection

Consumer Brands in One India

FY26 Revenue : INR 1,690 Cr

Consumer Brands in South Africa

FY26 Revenue : ZAR 1,590 Mn

One Africa

Cipla Actin
Respi OTC

CORYX
Cold and Cough

ASTHAVENT
Metered-dose inhaler

Respi OTC

acurate
pairs - hexapet hexadecile

BRENCOLO
Cold and Cough

Note:- Above numbers exclude sales of wellness brands through prescription channel

---

North America : Maintaining Strategic Focus Amid Near- Term Challenges
Cipla

Key Generic Drug Approvals

gVentolin

Liraglutide (gSaxenda & gVictoza)

Nintedanib

Dapagliflozin

Key Business Highlights

• Albuterol ranked No. 1 with total market¹ share at 19.6% (50 million+ inhaler units supplied to the U.S. market cumulatively)

• Received regulatory approval for the first AB-Rated gVentolin with CGT, representing the first commercial MDI product to be manufactured from our U.S. facility; launch is expected in coming months

• Market data as per IQVIA MAT Mar'26

---

Cipla

North America : Advancing Growth through a Strategic Asset Pipeline

Pipeline Progress

Respiratory Pipeline

• 5 assets filed (4 assets expected commercialization in FY 27)
• 4 assets to be filed in next 24 months
• 2 assets to be filed with green propellant in next 24 months

Peptides & Complex Generics

• 8 assets filed (select launches expected in FY27-FY28)
• 3 assets to be filed in next 12 to 24 months

Oligo / 505(b)(2) Differentiated Products

• 3 505(b)(2) and 2 Oligonucleotide filed
• 1 Oligonucleotide & 2 505(b)(2) assets to be filed over next 12-18 months
• 2 Global Biosimilar assets - one in clinical study and one in early stage of development

---

Cipla

ANDA & NDA Portfolio & Pipeline (As on 31st March 2026)

181
Approved ANDAs & NDAs
+
49
Tentatively Approved ANDAs & NDAs
+
55
Under Approval ANDAs & NDAs
=
285
Total ANDAs & NDAs

1. PEPFAR approved ANDAs can be commercialised in US

---

Cipla

One Africa¹: Continued Progress on Scaling-up Journey

Market Segment²	Rank	Share	Cipla Growth	Market Growth
South Africa Prescription	2	8.8%	9.6%	6.1%
South Africa OTC	3	8.1%	1.2%	2.5%
South Africa Overall	3	8.5%	6.6%	4.8%

1.4x Market² growth multiple

18 new launches

Across multiple therapies in FY26

SA Key Highlights²

• Healthy performance across key therapies like Respiratory, CNS, Alimentary TR and Metabolism
• 9 brands with MAT revenue > 100 Mn ZAR

• Highest number of brands in top 30 (7), top 50 (11) and top 100 (21) within generics segment

• One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT Feb'26

---

Cipla

Progress on ESG goals (India Manufacturing Operations) : FY26

Goals (India Manufacturing Operations by 2025)	Progress : FY 2026
80% reduction in absolute Scope 1 (energy based) and Scope 2 emissions from baseline year of FY 2019-20	Achieved 83%* reduction from the baseline year, as on CY Dec 2025
Water neutrality	Achieved 2.6 times water positive
Zero Waste to Landfill ('ZWTL')	• All Cipla India Manufacturing operations are ZWTL re-certified
• 24 units advanced from Platinum to Platinum+ certification
• Additionally, 2 warehouses ZWTL certified—one domestic in Pune and one international, Cipla Distribution Gateway (CDG) in South Africa
50% renewable electricity	>50% renewable electricity achieved
Continuing zero fatality in our manufacturing operations	Achieved Zero Fatality
Full compliance with safe discharge targets established by AMR Industry Alliance	Achieved full compliance with the safe discharge targets
Four AMR certified product – Azithromycin, Ofloxacin, Levofloxacin and Ciprofloxacin

Cipla (EU) Limited – Net Zero Commitment

• Cipla (EU) limited has committed to achieve net zero by 2050 and disclosed Carbon Reduction Plan (CRP).

Achievements and Recognition

☐ Cipla ranked by Business World as Top Sustainable Companies
➤ 5th in the Healthcare and Pharma sector and
➤ 46th among the top 60 companies, in India

*Emissions reduction data are currently under audit

---

Cipla

Consolidated Profit and Loss Statement Summary (Reported)

INR Cr

Particulars	Q4 FY26	FY26
Revenue from sale of products	6,464	27,712
Other operating income	77	451
Income from operations	6,541	28,163
Material cost	2,249	9,549
Employee benefits expense	1,414	5,366
Other expenses	1,881	7,322
Total expenses	5,544	22,238
Finance costs	13	54
Depreciation, impairment and amortisation expense*	425	1,253
Other income	148	882
Profit before exceptional items and tax	707	5,500
Exceptional Items	-	276
Profit before tax	707	5,224
Tax expenses	157	1,354
Share of associate	-8	-8
Profit for the period	543	3,862
Non-controlling interest	-12	-17
Profit for the period attributable to shareholders	555	3,879

*Includes impairment of associates INR 42 Cr

---

Consolidated Balance Sheet Summary (Reported)

Particulars		Mar-26	Mar-25
Net Tangible Assets		7,626	6,586
Goodwill & Intangibles		6,850	4,986
Investments		544	640
Other non-current assets		770	576
Advance tax assets (net)		568	411
Deferred tax assets (net)		748	591
Inventories		6,597	5,642
Cash and Cash Equivalents*		11,140	10,807
Trade receivable		5,620	5,506
Other Current Assets		1,873	1,471
Held for sale (net)		1	40
Total assets		42,377	37,257
Equity		34,432	31,193
Non-controlling interest		88	96
Borrowings		258	92
Lease Liabilities		356	346
Other non-current liabilities		269	159
Provisions		2,417	1,865
Trade Payable		3,230	2,837
Other liabilities		1,287	667
Total equity and liabilities		42,337	37,257

• Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances | Figures have been rounded off

INR Cr
Cipla

---

21

Cipla

Thank You

Registered Office :
Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

Diksha Maheshwari
Investor.Relations@cipla.com

For more information, please visit
www.cipla.com